Influenza A virus H1N1 subtype antigens (H1N1 antigens)

Influenza A virus H1N1 subtype antigens comprise the essential proteins of the H1N1 virus, primarily the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), as well as the M2 ion channel and internal components like the RNA-dependent RNA polymerase (RdRp) complex (NIH, 2024; CDC, 2024). HA is responsible for binding to host cell sialic acid receptors and mediating viral entry, while NA facilitates the release of progeny virions by cleaving these receptors (NIH, 2024; Wikipedia, 2024). These antigens are the primary focus of vaccine development, where they elicit neutralizing antibodies to prevent infection (CDC, 2024). Antiviral therapies target specific antigenic functions: neuraminidase inhibitors (e.g., oseltamivir) block viral spread, while cap-dependent endonuclease inhibitors (e.g., baloxavir marboxil) disrupt viral replication (NIH, 2024; Medscape, 2023). The high rate of mutation in these antigens, known as antigenic drift, and the potential for genetic reassortment, or antigenic shift, necessitate continuous monitoring and frequent updates to therapeutic and preventive strategies (NIH, 2024; CDC, 2024). Furthermore, internal proteins like the nucleoprotein (NP) and matrix proteins are involved in genome packaging and structural integrity, serving as additional targets for research (NIH, 2024). Overall, these antigens are central to the pathogenesis of H1N1 and the primary focus of global public health efforts to control influenza (CDC, 2024).

Other names

H1N1 viral proteinsInfluenza A/H1N1 antigensHemagglutininNeuraminidaseMatrix protein 2Polymerase acidic proteinPolymerase basic protein 1Polymerase basic protein 2NucleoproteinSwine flu antigensPandemic H1N1 antigens

The mechanisms of action for drugs targeting H1N1 antigens include the inhibition of viral neuraminidase to prevent the release of progeny virions from infected cells (e.g., oseltamivir, zanamivir), the inhibition of the cap-dependent endonuclease subunit of the viral RNA polymerase to block viral RNA transcription (e.g., baloxavir marboxil), and the blockade of the M2 ion channel to prevent viral uncoating (e.g., amantadine) (NIH, 2024; CDC, 2024). Additionally, vaccines target surface antigens like hemagglutinin to induce neutralizing antibodies that block viral attachment and entry into host cells (CDC, 2024). Other agents like favipiravir inhibit the RNA-dependent RNA polymerase directly to halt viral replication (NIH, 2024).